{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-004189","form_type":"8-K/A","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.057618+00:00","generated_at":"2026-06-21T12:16:14.612849+00:00","sec_items":["9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Chemomab appoints Matthew Frankel as Chief Medical Officer & VP Drug Development","bullets":["Start Date November 14, 2022; report to Chairman & CEO Dale Pfost.","Annual base salary of $450,000; target performance bonus of 45% of base salary.","Special milestone bonuses: $100,000 after 60 days, $100,000 after 120 days.","Granted option to purchase 125,000 ADSs vesting over 4 years (25% annual, rest monthly).","Employment is at-will; governed by New York law with mandatory arbitration."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-004189","json":"https://secwatch.observer/filing/0001178913-22-004189.json","markdown":"https://secwatch.observer/filing/0001178913-22-004189.md","text":"https://secwatch.observer/filing/0001178913-22-004189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/0001178913-22-004189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/zk2228824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:16:14.612849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}